GENE ONLINE|News &
Opinion
Blog

2020-02-11| Trials & Approvals

Trevena Inc. Gives Oliceridine Approval Another Shot

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

Complying with USFDA’s complete response letter (CRL), the Chesco, Pennsylvania-based biopharma has resubmitted the NDA for its opioid drug with additional study data and validation reports.

After suffering multiple setbacks in the past couple of years, Trevena Inc. has a reason to be optimistic about its lead drug. Today, it has announced the resubmission of New Drug Application (NDA) for intravenous (IV) Oliceridine, an analgesic intended for the management of moderate-to-severe acute pain. Oliceridine is an investigational G protein-selective mu-opioid receptor agonist that has a novel mechanism of action.

Following the advisory committee’s 8-7 vote against the approval, the drug was originally rejected by the FDA in late 2018 on grounds of insufficient safety data. “We continue to believe in the strength of the data and the ultimate approvability of oliceridine” Carrie L. Bourdow, the CEO had said while expressing her disappointment at the time. Soon after, the drug lost its breakthrough therapy designation too.

Trevena suffered another blow when a securities class action lawsuit was filed by Bernstein Liebhard, LLP on behalf of investors who bought the company’s shares between May 2, 2016, and October 8, 2018. The lawsuit accused Trevena of misleading shareholders by claiming successful meetings with the FDA regarding the drug’s Phase III evaluation plans. In reality, the regulatory body had expressed several disagreements with respect to dosing and primary endpoints. As a result, the company’s stocks plummeted several folds.

 

Adherence to CRL

The FDA had not requested any additional efficacy data in the CRL but had indicated that the submitted safety database is not of adequate size for the proposed dosing. As requested, the resubmitted NDA contained drug product validation reports, data from a multi-dose healthy volunteer QT study with placebo- and positive-control arms and nonclinical data that confirmed levels of an inactive metabolite. As per the agreements with the FDA, a maximum daily dose of 27 mg was specified.

“The resubmission of the Oliceridine NDA represents a significant milestone for the program and an important achievement for the company. I am thankful for the team’s commitment and diligent work to bring us to this exciting point,” said Bourdow. “We appreciate FDA’s guidance through the resubmission process and look forward to continuing to work closely with the Agency as they review our application.”

Related Article: Relief for Patients as Baudax Bio’s Non-Opioid Analgesic Wins FDA Approval

 

References
  1. https://www.trevena.com/investors/press-releases/detail/224/trevena-resubmits-new-drug-application-for-oliceridine
  2. https://www.trevena.com/investors/press-releases/detail/156/trevena-receives-complete-response-letter-for-oliceridine
  3. https://www.sec.gov/Archives/edgar/data/1429560/000110465919013379/a19-6098_18k.htm
  4. https://www.prnewswire.com/news-releases/trevena-class-action-lawsuit-bernstein-liebhard-llp-announces-that-a-securities-class-action-lawsuit-has-been-filed-against-trevena-inc–trvn-300729966.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
2024-03-11
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
LATEST
Innovative Cellular Mapping of BRCA-Related Breast Cancer Findings Reveals Novel Therapeutic Targets
2024-03-29
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top